Pα+ Psychedelic Bulletin #228: Inside the Lilly-Atai Deal; An Update on the GH-AtaiBeckley Patent Standoff; Field Reacts to FDA’s Guidance; Resilient Readies Resubmission

Getting anyone familiar with the specifics surrounding the Eli Lilly-AtaiBeckley deal to go on the record has been challenging, but we have spoken with people familiar with the details on the condition of anonymity. While Endpoints reports that other large pharmaceutical companies, including AbbVie and Johnson & Johnson, are said to have taken a look at AtaiBeckley, we also understand that Lilly…

Source